Table 1. Characteristics of Patients Diagnosed With Nonadvanced Cancers of the Colorectum, Lung, Prostate, or Breast Who Received Stage-Appropriate Treatment, by HIV Statusa.
| HIV Status, No. (%) | ||
|---|---|---|
| Infected (n = 288) | Uninfected (n = 307 980) | |
| Sex | ||
| Male | 224 (77.8) | 168 774 (54.8) |
| Female | 64 (22.2) | 139 206 (45.2) |
| Age at diagnosis, y | ||
| 65-69 | 134 (46.5) | 88 369 (28.7) |
| 70-75 | 94 (32.6) | 100 794 (32.7) |
| ≥76 | 60 (20.8) | 118 817 (38.6) |
| Race/ethnicity | ||
| White, non-Hispanic | 163 (56.6) | 264 604 (85.9) |
| Black, non-Hispanic | 106 (36.8) | 24 352 (7.9) |
| Hispanic | NRb | 4167 (1.4) |
| Asian | NR | 7599 (2.5) |
| Other/unknown | NR | 7258 (2.4) |
| Year of cancer diagnosis | ||
| 1996 to 2004 | 106 (36.8) | 123 215 (40.0) |
| 2005 to 2012 | 182 (63.2) | 184 765 (60.0) |
| Cancer site | ||
| Colorectum | 34 (11.8) | 49 623 (16.1) |
| Localc | 22 (64.7) | 32 745 (66.0) |
| Regional | 12 (35.3) | 16 878 (34.0) |
| Lung (NSCLC) | 34 (11.8) | 29 217 (9.5) |
| Local | >20 (>70.0)d | 17 663 (60.5) |
| Regional | <11 (<30.0) | 11 554 (39.6) |
| Nonadvanced prostate | 170 (59.0) | 133 016 (43.2) |
| Female breast | 50 (17.4) | 96 124 (31.2) |
| Local | 37 (74.0) | 69 054 (71.8) |
| Regional | 13 (26.0) | 27 070 (28.2) |
| Median income (by census tract), $e | ||
| <30 000 | 85 (29.5) | 42 202 (13.7) |
| 30 000-59 000 | 138 (47.9) | 174 148 (56.6) |
| >59 000 | 64 (22.2) | 90 309 (29.3) |
| Vital statusf | ||
| Alive | 157 (54.5) | 174 499 (56.7) |
| Deceased | 131 (45.5) | 133 481 (43.3) |
| Cancer deathg | 46 (35.1) | 43 336 (32.5) |
Abbreviations: NR, not reported; NSCLC, non–small cell lung cancer.
Data were obtained from the Surveillance, Epidemiology, and End Results (SEER)–Medicare linked database. Patients survived more than 1 year after cancer diagnosis and underwent the following treatment to be classified as receiving stage-appropriate treatment: (1) colorectal cancer—surgery for local disease, chemotherapy for regional-stage cancer; (2) NSCLC—surgery or radiation for local-stage cancer, chemotherapy for regional-stage cancer; (3) prostate cancer—receipt of surgery, radiation, or hormone therapy for nonadvanced cancer (no differentiation in SEER between local or regional-stage); (4) breast cancer—surgery for local- or regional-stage cancer.
Numbers lower than 11 are not reported in accordance with the SEER-Medicare data use agreement, but HIV-infected and HIV-uninfected patients did not differ substantially regarding these categories of racial/ethnic distribution.
Percentages calculated among diagnoses at the given cancer site.
Exact number not reported in accordance with the SEER-Medicare data use agreement, but approximate categories are shown to illustrate differences in NSCLC stage distribution by HIV status.
Percentages do not sum to 100% due to fewer than 1% of missing values for both HIV-infected and uninfected patients with cancer.
Vital status as of December 2014 was ascertained using Medicare and SEER death records.
Percentages were calculated among deceased patients.